Inhaled Nitric Oxide Delivery Systems Market Size, Share and Trends 2025 to 2034

Inhaled Nitric Oxide Delivery Systems Market Size and Forecast 2025 to 2034

The global inhaled nitric oxide delivery systems market size accounted for USD 360.81 million in 2024 and is expected to exceed around USD 562.47 million by 2034, growing at a CAGR of 4.54% from 2025 to 2034. The rising demand for rapid drug delivery devices with the ease in use and convenient for the patient with any types of respiratory disease are contributed in the growth of the market.

Inhaled Nitric Oxide Delivery Systems Market Key Takeaways

• North America dominated the global market with the largest market share of 40% in 2024.
• Asia Pacific is expected to show significant growth during the forecast period.
• By type, the pediatric segment contributed the highest market share of 76% in 2024.
• By type, the adult segment will witness significant growth during the forecast period.
• By product, the disposable segment captured the biggest market share in 2024.
• By product, the system segment will show rapid growth during the forecast period.
• By application, the hypoxic respiratory failure (HRF) segment generated the major market share in 2024.
• By application, the adult respiratory distress syndrome (ARDS) segment is expected to grow at the fastest CAGR during the forecast period.
• By end-user, the hospital segment has held the largest market share of 81% in 2024.
• By end-user, the ambulatory centers segment is projected to grow at the fastest CAGR in the future years.

How Can AI Impact the Inhaled Nitric Oxide Delivery Systems Market?

The adaptation of artificial intelligence into respiratory disease treatment enhances patient care with continuous monitoring of patient data such as blood gas levels, respiratory patterns, and lung mechanics. AI provides real-time insights into the ventilation parameters that ensure optimal support for patients' respiratory systems. The AI also enhances the quality of personalized respiratory treatment by detecting and analyzing patient history, symptoms of the condition, and response to therapies. AI-based algorithms can detect and analyze the symptoms of respiratory disease early and help physicians make informed decisions for treatment.

• In November 2024, SoundHealth, Inc., a healthcare technology organization focusing on the power of artificial intelligence and medical science to enhance patient outcomes, launched the SONUCheck, the innovative vocal analysis feature in the SONU app that uses voice noninvasive biomarker for measuring the nasal patency.

U.S. Inhaled Nitric Oxide Delivery Systems Market Size and Growth 2025 to 2034

The U.S. inhaled nitric oxide delivery systems market size was exhibited at USD 101.03 million in 2024 and is projected to be worth around USD 160.60 million by 2034, growing at a CAGR of 4.74% from 2025 to 2034.

North America dominated the inhaled nitric oxide delivery systems market in 2024. The growth of the market is attributed to the rising infrastructural development and the continuous investment by the regional government in the development of the healthcare system. The continuous advancement in the healthcare technology and pharmaceutical industry is driving the growth of the market. The increasing prevalence of respiratory disease in the population due to the changing environmental pollution, genetics, and changing lifestyles, such as the rising adoption of smoking, drives the demand for the efficient treatment of respiratory disease.

• In the United States, there are 4.3% of adults diagnosed with COPD, emphysema, or chronic bronchitis in 2023. 4.2% of COPD patients visit office-based physicians. 791,000 visits take place in emergency departments with COPD as the primary diagnosis.

Asia Pacific is expected to show significant growth in the inhaled nitric oxide delivery systems market during the forecast period. The growth of the market is increasing owing to the rising penetration of the different types of respiratory disease, including chronic obstructive pulmonary disease (COPD), neonatal respiratory distress syndrome (RDS), and others, which are driving the demand for nitric oxide supplements for the treatment of such types of disease is driving the demand for the inhaled nitric oxide delivery systems. The increasing investment by regional countries such as India, China, and Japan in improving healthcare infrastructure is accelerating the growth of the market across the region.

Market Overview

The inhaled nitric oxide delivery system is the medication process in which the nitric oxide is inhaled through the mouth and nose. It is the efficient delivery system that helps in effectively delivering the nitric oxide drug in a certain proportion into the body by the mouth or the nose. The inhaled nitric oxide delivery system is only given by the physician. There is an increasing prevalence of chronic respiratory disease in the population.

Inhaled Nitric Oxide Delivery Systems Market Growth Factors

• Increasing penetration of COPD: The rising number of cases of chronic obstructive pulmonary disorders in the population due to several factors is driving the demand for an effective and faster medication delivery system.
• Increasing healthcare infrastructure: The growing healthcare infrastructure and the development of medication for rapid drug delivery, as well as the ongoing investment in pharmaceuticals and biomedical applications.
• Government interventions: The increasing government intervention in the development of favorable initiatives and policies in the development of the healthcare infrastructure and the launch of new medication and delivery systems are accelerating the growth of the market.

Market Scope

Market Dynamics

Driver

The increasing awareness regarding nitric oxide

The rising use of nitric oxide in the healthcare industry for the treatment of several diseases and other awareness regarding the benefits associated with nitric oxide usage is accelerating the adoption of inhaled nitric oxide delivery systems. Nitric oxide supplements are used in different disease treatments, such as reducing high blood pressure, maintaining the blood flow in the body, treating erectile dysfunction, reducing muscle soreness, lowering blood pressure, and others.

Restraint

Side effects

The side effects associated with nitric oxide, such as its rapid reaction with the oxygen in the lung and form the nitrogen dioxide, potentially develop the pulmonary irritant, which may cause severe issues in the body that limit the adoption of the inhaled nitric oxide delivery systems market.

Opportunity

Incorporation of smart technology

The integration of smart technologies into the inhaled nitric oxide delivery systems, such as the incorporation of alarms and automatic shut-off features. The integration of smart features includes higher precision and control, real-time monitoring, enhanced safety features, and versatility. The government and industry leaders are increasing investments in the development and launch of new products.

Type Insights

The pediatric segment dominated the inhaled nitric oxide delivery systems market in 2024. The increasing penetration of respiratory disease in children due to genetics, environmental pollution, and other factors that cause the increased number of diseases, such as Persistent Pulmonary Hypertension and Hypoxic Respiratory Failure (HRF) of Newborns (PPHN), boosts the demand for inhaled nitric oxide delivery systems. Children and infants with pulmonary hypertension are treated with inhaled nitride oxide as it improves the ventilation-perfusion mismatch and reduces pulmonary vascular resistance. Continuous research and development programs contribute to further launching medication products.

• Asthma patients recorded 94,000 hospital inpatient stays and more than 900,000 visits to the Emergency department. There are 7.7% of Americans who have asthma, 24.9 million of the population have asthma, 20.2 million adults, and 4.6 million children. 147,382 deaths occurred due to chronic lower respiratory disease, including asthma, in 2022.

The adult segment will witness significant growth in the inhaled nitric oxide delivery systems market during the forecast period. The rising prevalence of chronic respiratory illness in the adult population, such as COPD, Acute Respiratory Distress Syndrome (ARDS), and others, is driving the growth of the inhaled nitride oxide delivery systems market. The rising awareness about nitric oxide supplements enhances performance during exercise, increases heart health, enhances the healing process, reduces and maintains high blood pressure, erectile dysfunction, and others.

Product Insights

The disposable segment accounted for a significant share of the inhaled nitric oxide delivery systems market in 2024. The increasing demand for single-use disposable medication products is driving the demand for the disposable inhaled nitric oxide delivery system. The increasing awareness regarding infectious diseases and cross-contamination is driving the demand for disposable medication products or systems.

The system segment will show rapid growth in the inhaled nitric oxide delivery systems market during the forecast period. The increasing adoption of the modern system due to ease of use and the increasing demand for the modernization of the medication system or devices from different healthcare settings, including clinics, hospitals, ambulatory services, and others.

Application Insights

The hypoxic respiratory failure (HRF) segment led the global inhaled nitric oxide delivery systems market in 2024. There is an increasing demand for nitric oxide supplements for the treatment of hypoxic respiratory failure owing to their medication benefits, such as improving ventilation-perfusion mismatch and reducing pulmonary vascular. The rising penetration of hypoxic respiratory failure in pediatric patients, such as infants and children.

The adult respiratory distress syndrome (ARDS) segment will observe substantial growth in the inhaled nitric oxide delivery systems market during the predicted period. The increasing number of respiratory distress syndrome in adults due to changing lifestyles, increasing adoption of habits like smoking, and environmental pollution are collectively driving the demand for nitric oxide supplements for the treatment of the disorders. 

End-user Insights

The hospital segment accounted for the largest share of the inhaled nitric oxide delivery systems market in 2024. The higher number of patients visiting for their health checkups and for the treatment of several diseases is causing the increasing demand for nitric oxide supplements by hospitals. The hospital is one of the leading healthcare institutes, has a larger capacity for patient administration, and is highly equipped with modern healthcare materials and equipment for the efficient treatment process.

The ambulatory centers segment will show significant growth in the inhaled nitric oxide delivery systems market during the forecast period. The rising popularity of ambulatory healthcare centers is due to the availability of all the essential and important equipment that is important for the treatment of patients. The ambulatory centers are cost-effective solutions to the expensive healthcare solutions.

Inhaled Nitric Oxide Delivery Systems Market Companies

• Mallinckrodt Pharmaceuticals
• Getinge AB
• VERO Biotech
• Linde plc
• Beyond Air, Inc.
• SLE Ltd.
• Bellerophon Therapeutics
• Air Liquide Healthcare
• Circassia Pharmaceuticals
• International Biomedical

Latest Announcement by Industry Leaders

• In November 2024, Mallinckrodt plc, a leading specialty pharmaceutical company, was awarded as the winner of the Extracorporeal Immunomodulation Award (EIA). The award is given for the contribution to the optimal timing for extracorporeal photopheresis (ECP) initiation and for assessing its efficiencies when integrated with other graft versus host disease (GvHD) therapies. 

Recent Development

• In October 2024, Mallinckrodt plc, a leading specialty pharmaceutical company, INOmax® EVOLVE™ DS delivery system for the delivery of INOmax® (nitric oxide) gas for inhalation cleared by the U.S. Food and Drug Administration (FDA). 
• In January 2023, VERO Biotech Inc., a commercial-stage healthcare organization focusing on the development of the neonatal intensive care and the acute care hospital community, announced its FDA approval for the tankless inhaled nitric oxide (iNO) delivery system. 
• In October 2024, Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company that works on the endogenous and exogenous nitric oxide (NO), partnered with Healthcare Links, a healthcare advisory group for the expansion of the Beyond Air’s LungFit® PH system with entry into the Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) across the United States. 

Segments Covered in the Report 

By Type 

• Pediatric
• Adult

By Product 

• Disposables
• System

By Application

• Hypoxic Respiratory Failure (HRF)
• Acute Hypoxemic Respiratory Failure (AHRF)
• Others

By End-user

• Hospitals
• Ambulatory Centers
• Clinics

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa